Welcome to our dedicated page for Nexgel SEC filings (Ticker: NXGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NexGel, Inc. filings document the formal disclosures of a Nasdaq-listed operating company focused on hydrogel-based healthcare, beauty and OTC products. Recent 8-K reports cover material definitive agreements, an exclusive license and asset purchase for regenerative biomaterial products, convertible-note financing, and capital-structure terms tied to common stock, notes and warrants.
The filings also record board and financial officer changes, employment and compensation arrangements, Nasdaq listing-compliance notices, Regulation FD communications, and exhibits to material contracts. These disclosures connect NexGel’s product expansion, financing activity, governance structure and public-company reporting obligations.
NexGel, Inc. filed a current report to disclose that it is using a new investor presentation as of June 17, 2026. The presentation is provided as Exhibit 99.1 and is being furnished under Regulation FD, meaning it is for information purposes and not treated as filed financial reporting.
The company states that this investor presentation will not be incorporated into other securities law filings unless specifically referenced. No new financial results, major transactions, or operational changes are described in this report itself.
NEXGEL, INC. Chief Executive Officer Adam R. Levy reported an open-market sale of common stock. On June 11, 2026, he sold 3,000 shares at $0.6136 per share. After this transaction, he continues to directly hold 333,692 shares of NEXGEL common stock.
NEXGEL, INC. Chief Executive Officer Adam R. Levy reported open-market sales of company common stock. He sold 3,000 shares at $0.5936 per share on June 4 and 3,000 shares at $0.5470 per share on June 8. After these transactions, he directly holds 336,692 shares of NEXGEL common stock, indicating he retained the vast majority of his position.
NexGel, Inc. is asking stockholders at its July 10, 2026 annual meeting to approve seven proposals, including a large potential share issuance tied to recent convertible note and warrant financings, a move from Delaware to Nevada, and significant changes to its capital structure.
Proposal 2 seeks approval under Nasdaq rules to issue more than 19.99% of currently outstanding common stock upon conversion of unsecured convertible notes and exercise of related warrants, which could result in substantial dilution if fully converted. Proposals 3–5 would reincorporate NexGel in Nevada and, either through the new Nevada charter or as Delaware fallbacks, increase authorized common stock from 25,000,000 to 100,000,000 and permit a discretionary 1‑for‑2 to 1‑for‑10 reverse stock split. As of the June 3, 2026 record date, 9,225,242 common shares were outstanding. Stockholders are also asked to elect seven directors, approve executive pay on an advisory basis, and ratify the 2026 auditor.
NEXGEL, INC. Chief Executive Officer Adam R. Levy reported an open-market sale of common stock. He sold 2,000 shares of Common Stock at a price of $0.5859 per share on June 1, 2026. After this transaction, he directly owned 342,692 shares of NEXGEL common stock, so the sale represents a small portion of his overall reported holdings.
NEXGEL, INC. Chief Executive Officer Adam R. Levy reported selling a total of 13,000 shares of Common Stock in open-market transactions over three days. He sold 3,000 shares at $0.5975 per share, 7,000 shares at a weighted average price of $0.6058 per share, and 3,000 shares at $0.6003 per share. Following these sales, he directly holds 344,692 shares of NEXGEL Common Stock, indicating these sales represent a relatively small portion of his overall position.
NexGel, Inc. seeks stockholder approval at its 2026 Annual Meeting for seven proposals, most notably shareholder approval under Nasdaq rules to permit issuance of shares exceeding 19.99% upon conversion of convertible notes and exercise of warrants from its April and May 2026 private financings. The proxy also asks to approve reincorporation from Delaware to Nevada (including authorization of 100,000,000 authorized common shares and a discretionary reverse split authority of 1-for-2 to 1-for-10), fallback Delaware amendments increasing authorized shares from 25,000,000 to 100,000,000, an advisory say-on-pay vote, and ratification of auditors. The proxy discloses Financings that include unsecured convertible notes (initial conversion price $0.60) and warrants (exercise price $0.80), related-party participation, and illustrative dilution tables showing up to 31,900,001 underlying shares at initial prices.
NEXGEL director Henry Scott Robert acquired new derivative securities linked to the company’s common stock. He received a Convertible Promissory Note with an original principal amount of $25,000, which is convertible into up to 41,667 shares of common stock at an initial conversion price of $0.60 per share.
He also received a Warrant to Purchase Common Stock for 20,834 shares at an initial exercise price of $0.80 per share. Both the note and warrant are exercisable at his option, subject to a 4.99% beneficial-ownership limitation and other specified conditions.
NEXGEL director Brian Joseph Kieser bought a $1,000,000 Convertible Promissory Note and received a large stock warrant as part of the same financing. The Note can be converted into up to 1,666,667 shares of common stock at $0.60 per share. The warrant is exercisable for 833,334 shares at $0.80 per share. Both instruments are convertible or exercisable at the holder’s option but are subject to a 4.99% beneficial-ownership limitation on NEXGEL’s outstanding common stock.